Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967041 | 0.97 | KDM4E (0.57) | KDM4EALDH1A1TSHRSMN1; SMN2NPC1 | |
| SCHEMBL4967027 | 0.84 | FFAR4 (0.48) | ALDH1A1TSHRSMN1; SMN2LMNAPKM | |
| SCHEMBL4969033 | 0.82 | FFAR4 (0.49) | KDM4EALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL4969247 | 0.82 | HTR6 (0.51) | ALDH1A1SMN1; SMN2LMNAPKMHPGD | |
| SCHEMBL4969886 | 0.82 | FFAR4 (0.46) | ALDH1A1SMN1; SMN2NPC1LMNAPKM | |
| SCHEMBL4966735 | 0.81 | KMT2A (0.67) | KDM4EALDH1A1TSHRSMN1; SMN2NPC1 | |
| SCHEMBL4967937 | 0.79 | HPGD (0.57) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL4000515 | 0.77 | KMT2A (0.53) | KDM4EALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL1874466 | 0.74 | LMNA (0.72) | ALDH1A1TSHRSMN1; SMN2LMNAPKM | |
| SCHEMBL4003328 | 0.73 | KMT2A (0.56) | KDM4EALDH1A1SMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1670790-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | TBXA2R, CYP2C19, CYP3A43 | KDM4E 2132/4885ALDH1A1 93/4885TSHR 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.